Last reviewed · How we verify
Riboflavin/Dextran
Riboflavin is activated by light to generate reactive oxygen species that cross-link corneal collagen, while dextran acts as an osmotic agent to facilitate corneal hydration during the procedure.
Riboflavin is activated by light to generate reactive oxygen species that cross-link corneal collagen, while dextran acts as an osmotic agent to facilitate corneal hydration during the procedure. Used for Keratoconus (progressive), Post-refractive surgery corneal ectasia, Corneal weakening and ectasia prevention.
At a glance
| Generic name | Riboflavin/Dextran |
|---|---|
| Also known as | Riboflavin in a dextran solution |
| Sponsor | Cornea and Laser Eye Institute |
| Drug class | Corneal cross-linking agent |
| Target | Corneal collagen (indirect via photochemical cross-linking) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
This combination is used in corneal cross-linking, a procedure to strengthen corneal tissue and halt progression of keratoconus and corneal ectasia. Riboflavin (vitamin B2) absorbs ultraviolet-A light and generates singlet oxygen that creates covalent cross-links between collagen fibers, increasing corneal rigidity. Dextran serves as a carrier and osmotic agent to maintain corneal clarity and proper hydration during the photochemical reaction.
Approved indications
- Keratoconus (progressive)
- Post-refractive surgery corneal ectasia
- Corneal weakening and ectasia prevention
Common side effects
- Corneal haze
- Temporary vision reduction
- Corneal scarring
- Dry eye
Key clinical trials
- ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty (PHASE2)
- Epi-on CuRV and Epi-off aCXL Protocols in the Management of Keratoconus
- Steroids and Cross-linking for Ulcer Treatment (PHASE3)
- German Corneal Cross Linking Register
- Pretreatment to Promote Graft Survival After Subsequent High-risk Corneal Transplantation [CrossCornealVision] (NA)
- Collagen Crosslinking for Keratoconus - a Randomized Controlled Clinical Trial (PHASE3)
- Corneal Collagen Crosslinking to Increase the Resistance of the Support Graft of the KPro Type I Against Corneal Melting (NA)
- Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive Surgery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |